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The airways are made up of ciliated epithelium which 
secretes mucous, protecting the respiratory tract from 
particles inhaled during breathing. Its is paramount to 
understand the physiology and the mechanisms involved 
in mucociliary activity. Literature suggests that Nitric oxide 
(NO), especially the one produced by iNOS expression, 
maintains the mucociliary function and the immune defense 
of the nasal cavity. Aim: to assess NO participation and the 
enzymatic pathways in the production of NO and mucociliary 
transport, using constructive and inductive NO synthetase 
inhibitors, L-NAME and aminoguanidine, respectively. 
Materials and methods: frog palates were prepared and 
immerse in ringer (control), L-NAME or aminoguanidine 
solutions. The palates were immerse in these solutions for 
four periods of 15 minutes. Mucociliary transport measures 
were carried out before and after each exposure. Results: 
control palates maintained stable their transportation speed. 
L-NAME increased, while aminoguanidine reduced mucous 
transportation velocity. Conclusion: unspecific cNOS 
block with L-NAME and relatively specific iNOS block with 
aminoguanidine results leads us to propose that depending 
on the pathway, the NO can increase or reduce mucociliary 
transport in frog palates. 
Keywords: mucociliary clearance, enzyme inhibitors, 
respiratory mucosa.
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INTRODUCTION
The respiratory system is the first inner region of 
the body to make contact with the external environment. 
Airways are the first interface between the internal milieu 
and microorganisms, allergens, or inhaled particles. A 
variety of particles and chemical substances are deposited 
in the respiratory apparatus during breathing.
The respiratory tract has a sophisticated defense 
mechanism, the mucociliary apparatus, to support the 
homeostasis of this delicate system.1 The airway mucosa, 
from the nasal cavity to the bronchioles, consists of pseu-
dostratified and ciliated epithelium interspaced by sub-
mucosal glands and goblet cells, which produce mucus.
Mucociliary transport is an important defense me-
chanism for the respiratory mucosa; it removes inhaled 
particles from this surface. The driving force for this 
complex system is the ciliary activity on the respiratory 
epithelium, commonly quantified by the ciliary beat 
frequency2 a measure of mucociliary transport velocity.3
The efficiency of mucociliary transport depends 
mainly on: the thickness of the mucus layer and the com-
position and rheological properties of mucus; cilia in cells 
with perfectly preserved structures, to efficiently perform 
ciliary movement; coordination among adjacent cilia to 
yield a beat wave for propulsion of mucus.4,5 Failure of 
the ciliary system may result in: easier bacterial coloni-
zation, thus increasing the risk of respiratory infections; 
increased contact time between harmful agents and the 
respiratory epithelium; stasis of mucus that may result in 
ventilation disorders and increased airflow resistance.6 
Thus, mucociliary transport dysfunction may worsen 
the quality of life of individuals. It is therefore crucial to 
understand the physiology of the mucociliary apparatus, 
how its components affect the clearance of respiratory 
secretions, and what are the control mechanisms and the 
actions of endogenous substances on mucociliary activity.
Seromucus glands are located in the submucosa in 
the nasal cavity. Goblet cells are prevalent in the paranasal 
sinus.7 Nasal mucus consists of goblet cell, submucosal 
gland and lacrimal gland secretions mixed with water. 
The composition of mucus is altered in pathological 
conditions, which directly or indirectly affect mucociliary 
function.8
The autonomic system is the most important nasal 
secretion control mechanism; parasympatic stimuli incre-
ase secretion volume. Other non-acetylcholine-mediated 
mechanisms, however, have been suggested.8
The lungs are the main nitric oxide (NO) producing 
site in the blood circulatory system.9 NO is produced 
from L-arginine (L-Arg) in airways and is a component 
of physiological and pathophysiological events such as 
vasodilatation, broncodilatation, neurotransmission and 
bacteriostasis.10 NO production is set in motion by the 
NO synthase enzyme (NOS). There are three distinct iso-
forms of NOS: endothelial NOS (eNOS), neuronal NOS 
(nNOS), both of which are expressed constitutively and 
named cNOS, and an inductive pathway (iNOS). These 
three NOS isoforms may be found in the respiratory tract, 
and add to NO production.11 It has been shown that NO 
production takes place due to continuous expression 
of iNOS in epithelial cells within the airways of healthy 
individuals. This enzyme appears to have a crucial role 
in defending the airways against infection.12
Topical application of NG-nitro-L-arginine-methyl-
ester (L-NAME), a cNOS inhibitor, reduced nasal NO con-
centrations. Topical application of sodium nitroprussiate, 
an NO donor, increased nasal NO and decreased the 
transport time of nasal saccharine, which is an indicator 
of mucociliary function. Additionally, L-NAME prolonged 
the transport time. These observations suggested that 
artificially changing nasal NO production could affect 
mucociliary function.13
The concentration of nasal NO is decreased in 
acute and chronic rhinosinusitis, cystic fibrosis, primary 
ciliary dysfunction, chronic coughing, and exposure to 
tobacco and alcohol; these conditions are characterized 
by altered upper airway ciliary mucosal histology.14 Low 
NO production due to iNOS in the maxillary sinuses of 
rhinosinusitis and septicemia patients has been associated 
with a decreased function of defense mechanisms and an 
increased risk of secondary infections.15
It has been suggested that NO production due to 
iNOS is increased in the nasal epithelium of allergic rhinitis 
patients. A study of acetylcholine and L-NAME showed 
that although baseline nasal ciliary activity depends on 
endogenous NO production, cilia may be stimulated by 
cholinergic16 or mechanical17 stimuli regardless of endo-
genous NO production. For these two stimuli, the joint 
action of NO on ciliary beats improves local defense 
against allergens in allergic rhinitis patients.
Cilia move by using energy stored as ATP in mi-
tochondria; thus, cilia continue to move even when the 
blood supply is interrupted, as long as local conditions 
are favorable, until all ATP is consumed. A convenient 
system for studying mucociliary transport is the frog palate; 
it is ciliated and secretes mucus similar to what is found 
in human airways.1,3
The purpose of this study was to assess the role 
of NO in regulating ciliary transportability under normal 
conditions. The effects of NO producing constitutive 
and inductive enzyme inhibitors on mucociliary trans-
portability in frog palates were studied with the aim of 
observing how NO participated in this mechanisms and 
characterizing the NO production pathway involved with 
mucociliary transportability.
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MATERIAL AND METHODS
The sample consisted of 85 adult frogs of both se-
xes of the species Rana catesbiana, weighing from 90 to 
150 g, acquired from a commercial frog farm. The frogs 
were kept in appropriate boxes at 23oC±2.0. The palates 
were harvested by placing the frogs in cold water until 
sensitivity to mechanical stimuli was lost, after which they 
were sacrificed by decapitation; the mandible was then di-
sarticulated and the upper portion (palate) was separated. 
Palates were kept at 4oC in a closed chamber for 72 hours 
to deplete the mucus. Palates were removed from the 
refrigerator 20 minutes before the experiment and placed 
in an acrylic chamber coupled to an ultrasound nebulizer 
to keep the environment within the chamber at 100% hu-
midity; they were then saturated with a modified Ringer’s 
solution for frogs (one part of Ringer’s solutions and one 
part of distilled water - RingerR). During this period, the 
palate temperature increased to ambient temperature; the 
temperature inside the acrylic chamber was 24ºC. Sam-
ples of mucus were taken from the posterior portion of 
the palates and immediately immersed in mineral oil to 
avoid dehydration. Under such experimental conditions, 
the mucus layer is depleted, but ciliary activity remains.18,1
There were nine experimental groups of frog pala-
tes in this study. Five groups were used for assessing NO 
action (due to iNOS activation) on mucociliary transport 
velocity. Aminoguanidine was used for blocking iNOS 
in four groups comprising palates immersed in RingerR-
diluted aminoguanidine solutions at 40 ppm (N=8), 50 
ppm (N=10), 60 ppm (N=10) and 80 ppm (N=8); there was 
a control group (N=9) consisting of palates immersed in 
a RingerR solution only. The action of NO (due to cNOS 
activation) on mucociliary transport velocity was assessed 
in the other four groups of palates. Non-specific blockage 
of this pathway was attained by using L-NAME in three 
groups of palates immersed in a RingerR-diluted L-NAME 
solution at 120 ppm (N=10), 180 ppm (N=10) and 240 
ppm (N=10); there was a control group (N=9) consisting 
of palates immersed in a RingerR solution only.
A similar procedure was applied to expose all 
palates: immersion in a RingerR solution or in one of 
the aminoguanidine or L-NAME solutions during four 
consecutive 15-minute periods. Mucociliary transport was 
assessed before and after each of the palate immersion 
periods, according to the proposed technique.19 Mucoci-
liary transport was established by measuring the autolo-
gous mucus sample displacement velocity on the surface 
of mucus-depleted frog palates. Mucociliary transport 
velocity was established by measuring the time taken for 
mucus to move from the anterior to the posterior portion 
of the palate, using a stereoscope equipped with a measu-
rement scale with a grid in one of its eyepieces.3 Samples 
of mucus were immersed in ethyl ether to remove the 
mineral oil before being placed on palate surfaces.18 Five 
measurements were made of each velocity to minimize 
errors.20 Palates remained inside the acrylic chamber at 
100% humidity and temperature of 24ºC during the me-
asurements.
The final results were expressed as relative trans-
port velocities, obtained by dividing the recorded palate 
transport velocity at 15, 30, 45 and 60 minutes by the 
recorded velocity at time zero before immersions (the 
baseline velocity).19 
This study project was accepted by the Institutional 
Review Board on animal experimentation (number 41/05).
The mean relative transport velocities in all groups 
were compared based on the one-way analysis of variance 
(ANOVA) and by applying the Newman-Keuls multiple 
comparisons test for characterizing differences among 
results for each of the solutions and their concentrations, 
as well as the differences in immersion times for any same 
solution. The significance level was 5%.
RESULTS
The transport velocity in palates immersed in 
RingerR’s solution (controls) was statistically similar to 
baseline values across the transport velocity evaluation 
period, that is, after each immersion in RingerR’s solution.
Aminoguanidine decreased the mucociliary trans-
port velocity, which appeared to be time-related, albeit 
not statistically significant. In the four aminoguanidine 
solutions of the experiment, the 50 ppm and the 60 ppm 
solutions showed decreased mucociliary transport velocity 
compared to controls (Fig. 1).
Figure 1. Relative velocity of mucociliary transport in frog palates im-
mersed in RingerR’s solution (controls) or in 40 ppm, 50 ppm, 60 ppm 
or 80 ppm aminoguanidine solutions.
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In opposition to aminoguanidine, L-NAME increa-
sed the mucociliary transport velocity. The L-NAME 120 
and 180 ppm solutions did not increase the transport 
velocity significantly compared to controls. Velocity, ho-
wever, increased with immersion time in an L-NAME 180 
ppm solution, with a statistical difference between the 
15-minute and the 45 and 60-minute immersion periods. 
A significant increased in transport velocity occurred in 
palates immersed in the L-NAME 240 ppm solution, com-
pared to controls and to palates immersed in a 120 ppm 
solution. For immersion times, velocities recorded after 15, 
30, 45 or 60 minutes were statistically different in palates 
immersed in a 240 ppm solution (Fig. 2).
shown that NO operates as an intermediate messenger 
responding to these stimuli in the ciliated epithelium, but 
that NO-dependent mechanisms did not constitute a single 
pathway for stimulating ciliary function.22 Subsequently, 
sodium nitroprussiate (an NO donor) was found to de-
crease the saccharine transport time, while L-NAME was 
found to decrease nasal NO and to prolong the sacchari-
ne transport time in healthy subjects pre-treated with an 
anticholinergic drug.13
Results of a study done with L-arg and L-NAME 
have suggested that NO may have a regulating function 
on ciliary motility in the paranasal sinus mucosa of healthy 
subjects, and that eNOS and iNOS produce NO in healthy 
mucosae; it appeared further that eNOS seemed to have 
a more important role in producing NO.23
In our study we found that L-NAME increased mu-
cociliary transport velocity in frog palates compared to 
velocities before immersing these palates in an L-NAME 
solution. This differs from the proposition that L-NAME 
decreases ciliary activity. It should be noted that L-NAME, 
being a non-specific cNOS inhibitor, and depending 
on the dose, may also block iNOS action.24,9 We used 
L-NAME and aminoguanidine to block cNOS and iNOS 
in turn, obtaining different and antagonic results, which 
suggests that blockage was selective, and that the muco-
ciliary transport role of NO depends on which enzymatic 
pathway is activated.
Other studies of NO action have shown different 
results. Instillation of a lipopolysaccharide (E coli cell 
wall component that sets infection processes in motion) 
in the nasal cavity of guinea-pigs resulted in significantly 
increased NO production, which was harmful for the res-
piratory ciliated epithelium by causing damage to ciliated 
epithelial cells and decreasing the ciliary beat frequency.25 
It has been suggested that in otitis media, the contradictory 
action of NO may be explained by different NO reactions 
in specific biological conditions. Low NO production in 
physiological conditions may have regulating or anti-
inflammatory functions. In pathological conditions - such 
as inflammation - iNOS is activated and NO production 
increases.26 In the maxillary sinuses of healthy subjects, 
however, iNOS-expressed NO production was thought to 
support ciliary function and immune defenses, while in 
rhinosinusitis and septicemia, NO production decreased 
due to reduced iNOS activity, which led to compromi-
sed local defenses and an increased risk of secondary 
infections.15
It has subsequently been proposed that under 
normal conditions, NO is produced mainly by the iNOS 
pathway in nasal sinus epithelial cells, and under inflam-
matory conditions, NO is produced by the iNOS pathway 
in inflammatory cells. The iNOS activity in sinus epithelium 
Figure 2. Relative velocity of mucociliary transport in frog palates 
immersed in RingerR’s solution (controls) or in L-NAME solutions.
DISCUSSION
In this study we decided to study mucociliary 
transport in the frog palate; this palate is ciliated and se-
cretes mucus, similar to human airways.1,3 This approach 
attempted to assess NO and NO-production pathway 
(cNOS and iNOS) involvement in mucociliary transporta-
bility. Our study showed that using L-NAME to inhibit the 
NO production constitutive pathway resulted in increased 
mucociliary transport velocity, and that aminoguanidine-
induced inhibition of the inductive pathway resulted in 
decreased transport times.
Several studies have demonstrated NO involvement 
in ciliary activity. Studies of the rabbit maxillary sinus have 
shown that L-arg increases the ciliary beat frequency, 
and that this effect is decreased after NOS is blocked 
by N(G)-nitro L-arginine (L-NNA).21 Ciliary stimulation 
by NO-mediated transmitter or mediator substances has 
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appears to be essential for constant NO production, whi-
ch is needed for maintaining ciliary beats at an optimal 
frequency for ideal mucociliary clearance, thus keeping 
the sinuses healthy. In rhinosinusitis, iNOS expression in 
epithelial cells decreases, but NO production by iNOS 
in host defense cells in the nasal cavity increases signi-
ficantly. In such a process, significant amounts of NO 
and its metabolites may have a fundamental role in the 
pathogenesis of rhinosinusitis.27
Our study showed that the mucociliary transport ve-
locity in palates immersed in an aminoguanidine solution 
decreased, compared to the mean velocity before immer-
sion. Concentrations of 50 ppm and 60 ppm were the most 
effective inhibitory doses, suggesting dose adaptation for 
the enzyme inhibitory response in frog palates. Our results 
confirm that in healthy frog epithelium, iNOS-produced 
NO promotes mucociliary transport, since iNOS inhibition 
by aminoguanidine decreased transport velocity.
CONCLUSION
Non-specific blockage of cNOS by L-NAME and a 
relatively specific blockage of iNOS by aminoguanidine 
allowed us to propose that, depending on the produc-
tion pathway, NO may increase or decrease mucociliary 
transport in frog palates, suggesting a double role for NO 
in mucociliary transport in this epithelium.
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